5.

凡德他尼二线治疗晚期非小细胞肺癌的已完成的Ⅱ期试验结果

Results of completed phase Ⅱ trials of vandetanib as second-line therapy for advanced non–small-cell lung cancer

	中位PFS (周）	中位OS (月）	ORR (%)
aStudy met its primary endpoint significance criteria. bHR is compared with placebo + docetaxel. Abbreviations: D=docetaxel; G=gefitinib; HR=hazard ratio; NS=not significant; NSCLC=non–small-cell lung cancer; OS=overall survival; ORR=overall response rate; PFS=progression-free survival; V=vandetanib. Note: Reprinted with permission from the copyright holder ©CIG Media Group, LP a研究达到主要终点的意义标准。bHR与安慰剂+多西紫杉醇组比较。缩写：D：多西紫杉醇；G：吉非替尼；HR：危险比；NS：无意义；NSCLC：非小细胞肺癌；OS：总生存期；ORR：总有效率；PFS：无进展生存期；V：凡德他尼。 注：本图得到版权所有者©CIG Media Group, LP复制许可
试验3 V (300 mg) Versus G (250 mg)[60]; n=168	V:11	V: 6.1	V:8 G:1
	G:8.1	G:7.4
	HR=0.69;P=0.025a	HR=1.19;P=0.34
试验6 V (100 mg)+D (75 mg/m2) Versus V (300 mg)+D (75 mg/m2) Versus Placebo+D (75 mg/m2)[62]; n=127	V (100)+D: 18.7; bHR (V100)=0.64; P=0.074a V (300)+D: 17.0; bHR (V300)=0.83; P=0.416 D: 12.0	V(100)+D:13.1	V(100)+D:26
		V (300)+D: 7.9	V(300)+D:18
		D:13.4	D:12
		P=NS